Olaparib 99% Purity PARP Inhibitor CAS 763113-22-0 Small Molecule Anticancer Compound Research Grade

Product Overview

Olaparib is a potent, orally bioavailable poly (ADP-ribose) polymerase (PARP) inhibitor that targets DNA repair pathways. It selectively inhibits PARP-1 and PARP-2 enzymes, which play critical roles in DNA damage repair. By blocking PARP activity, olaparib induces synthetic lethality in tumor cells with BRCA1/2 mutations, making it a breakthrough targeted therapy for ovarian, breast, prostate, and pancreatic cancers. Marketed under the brand name Lynparza, olaparib was the first PARP inhibitor approved by the FDA and has become a cornerstone of precision oncology.

Chemically, olaparib is 4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one with the molecular formula C₂₄H₂₃FN₄O₃ and a molecular weight of 434.46 g/mol. It is a white to off-white crystalline powder with solubility in DMSO and DMF. The compound exhibits high target selectivity and favorable pharmacokinetic properties, including good oral bioavailability and tissue penetration.

Mechanism of Action

Olaparib exerts its anticancer effects through a dual mechanism of action:

• PARP Enzyme Inhibition: Potently and selectively inhibits PARP-1 and PARP-2, enzymes essential for base excision repair of single-strand DNA breaks

• Synthetic Lethality: In BRCA-mutated tumor cells with defective homologous recombination repair, PARP inhibition leads to accumulation of double-strand DNA breaks and apoptotic cell death

• PARP Trapping: Traps PARP enzymes on damaged DNA sites, further enhancing cytotoxicity and preventing DNA repair

• Tumor Selectivity: Preferentially targets cancer cells with DNA repair deficiencies while sparing normal cells with intact repair pathways

Research Applications & Market Significance

Olaparib represents a paradigm shift in targeted cancer therapy and continues to expand its clinical indications:

• Ovarian Cancer: First-line maintenance treatment for BRCA-mutated advanced ovarian cancer, significantly extending progression-free survival

• Breast Cancer: Approved for metastatic BRCA-mutated HER2-negative breast cancer, including triple-negative subtypes

• Prostate Cancer: Indicated for metastatic castration-resistant prostate cancer with homologous recombination repair gene mutations

• Pancreatic Cancer: Maintenance treatment for germline BRCA-mutated metastatic pancreatic adenocarcinoma

• Combination Therapy Research: Extensive clinical trials investigating combinations with immunotherapies, angiogenesis inhibitors, and other targeted agents

The global PARP inhibitor market is projected to exceed $20 billion by 2028, driven by expanding indications and growing adoption in precision medicine. Olaparib continues to lead the PARP inhibitor class with the broadest indication portfolio and strong clinical data supporting its use across multiple tumor types.

Quality Specifications

Our olaparib is manufactured under strict quality control conditions and meets the highest pharmaceutical standards:

• Purity: ≥99.0% determined by HPLC

• Identity confirmed by NMR, mass spectrometry, and elemental analysis

• Water content: ≤0.5%

• Residual solvents: Meet ICH Q3C guidelines

• Heavy metals: ≤10 ppm

• Related substances: Each impurity ≤0.1%, total impurities ≤0.5%

• Each batch accompanied by comprehensive Certificate of Analysis (COA)

• Stable for 24 months when stored at 2-8°C in sealed containers protected from light

Packaging & Shipping

We offer flexible packaging options to meet diverse customer needs:

• Research quantities: 100mg, 250mg, 500mg, 1g amber glass vials

• Bulk quantities: 5g, 10g, 50g, 100g amber glass bottles

• Industrial quantities: 1kg, 5kg, 25kg fiber drums with PE liners

• Custom packaging available upon request

• Shipped at ambient temperature for routine orders

• Cold chain shipping available upon request for temperature-sensitive orders

• International shipping with proper documentation including MSDS and COA

Specification Data Sheet